In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications—A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B

• Published in: Molecules
• Main Authors: Ottanà, Rosaria, Paoli, Paolo, Cappiello, Mario, Nguyen, Trung Ngoc, Adornato, Ilenia, Del Corso, Antonella, Genovese, Massimo, Nesi, Ilaria, Moschini, Roberta, Naß, Alexandra, Wolber, Gerhard, Maccari, Rosanna
• Format: Text
• Language: English
• Published: MDPI 2021
• Subjects: Article; DML
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828111/; http://www.ncbi.nlm.nih.gov/pubmed/33435264; https://doi.org/10.3390/molecules26020330

Diabetes mellitus (DM) is a complex disease which currently affects more than 460 million people and is one of the leading cause of death worldwide. Its development implies numerous metabolic dysfunctions and the onset of hyperglycaemia-induced chronic complications. Multiple ligands can be rationally designed for the treatment of multifactorial diseases, such as DM, with the precise aim of simultaneously controlling multiple pathogenic mechanisms related to the disease and providing a more effective and safer therapeutic treatment compared to combinations of selective drugs. Starting from our previous findings that highlighted the possibility to target both aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands (DMLs). Out of the tested compounds, 4f exhibited well-balanced AR/PTP1B inhibitory effects at low micromolar concentrations, along with interesting insulin-sensitizing activity in murine C2C12 cell cultures. The SARs here highlighted along with their rationalization by in silico docking experiments into both target enzymes provide further insights into this class of inhibitors for their development as potential DML antidiabetic candidates.